Sapropterin Dihydrochloride Tablet
Product Images NDC 72603-191

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 4 technical images submitted to the FDA as part of the official labeling for Sapropterin Dihydrochloride (NDC 72603-191). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Northstar Rxllc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Sapropterindihydrochloridetabletscontainerlabel (Sapropterindihydrochloridetabletscontainerlabel)

Sapropterindihydrochloridetabletscontainerlabel (Sapropterindihydrochloridetabletscontainerlabel)
Label for Sapropterin Dihydrochloride Tablets, 100 mg strength, containing 120 tablets. The label includes dosage form as tablets and notes the product is manufactured for Northstar Rx LLC. It also specifies storage instructions and batch coding area, with bar code and NDC 72603-191 visible.*
FDA Label Image

Sapropterindihydrochloridetabletsfigure1 (Sapropterindihydrochloridetabletsfigure1)

Sapropterindihydrochloridetabletsfigure1 (Sapropterindihydrochloridetabletsfigure1)
A line graph showing blood phenylalanine (Phe) levels in micromoles per liter over a 6-month study period. Two groups are represented: children aged 1 month to under 2 years (solid line) and children aged 2 to under 7 years (dashed line). The graph includes error bars and a dotted line indicating the target blood Phe control range. Blood Phe levels fluctuate initially before stabilizing near the target range over time.*
FDA Label Image

Sapropterindihydrochloridetabletsfigure2 (Sapropterindihydrochloridetabletsfigure2)

Sapropterindihydrochloridetabletsfigure2 (Sapropterindihydrochloridetabletsfigure2)
A line graph showing blood phenylalanine (Phe) levels over time during study visits from week -2 to week 6. Two groups are compared: Sapropterin Dihydrochloride (solid circles) and Placebo (open circles). The graph indicates lower Phe levels for the Sapropterin group starting at week 0, with a significant difference (p < 0.001). Error bars represent variability at each time point.*
FDA Label Image

Sapropterindihydrochloridetabletsstructure (Sapropterindihydrochloridetabletsstructure)

Sapropterindihydrochloridetabletsstructure (Sapropterindihydrochloridetabletsstructure)
Chemical structure diagram of sapropterin dihydrochloride showing the molecular arrangement, including labeled positions and the two hydrochloride components (2 HCl).*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.